Alpha-adrenergic blocking drugs in clinical medicine

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 7-16

  Frishman, William H ^a,c   Kotob, Fayez ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; INDORAMIN; METOPROLOL; PHENOXYBENZAMINE; PHENTOLAMINE; PLACEBO; PRAZOSIN; TAMSULOSIN; TERAZOSIN; TRIMAZOSIN; YOHIMBINE;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LUNG DISEASE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PHEOCHROMOCYTOMA; PROSTATE HYPERTROPHY; REVIEW; RHINORRHEA; SHOCK; TACHYCARDIA;

ADRENERGIC ALPHA-ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; PHEOCHROMOCYTOMA; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC;

EID: 0032920669     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007516     Document Type: Review

References (72)

1. Ahlquist RP: Study of the adrenotropic receptors. Am J Physiol 1948;153:486.
2. Lands AM, Luduena FP, Buzzo HJ: Differentiation of receptor systems responsive to isoproterenol. Life Sci 1967;6:2241-2249.
3. 3-adrenergic receptor. Science 1989;245:1118-1121.
4. Berthelsen S, Pettinger WA: A functional basis for classification of alpha-adrenergic receptors. Life Sci 1977;21:595-606.
5. Minneman KP, Ebenshade TA: α-adrenergic receptor subtypes. Ann Rev Pharmacol Toxicol 1994;34:117-133.
6. 1-adrenoreceptors and uroselectivity. Prostate 1997;33:202-215.
7. Sutherland EW, Robinson GA, Butcher RW: Some aspects of the biological role of adenosine 3′5′-monophosphate (cyclic AMP). Circulation 1968;37:279-306.
8. Insel PA: Adrenergic receptors: evolving concepts and clinical implications. N Engl J Med 1996;334:580-585.
9. Lefkowitz RJ, Caron MG. Adrenergic receptors: models for the study of receptors coupled to guanine nucleotide regulatory proteins. J Biol Chem 1988;263:4993-4996.
10. Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ: Regulation of adenyl cyclase-coupled beta-adrenergic receptors. Ann Rev Cell Biol 1988;4:405-428.
11. Limbird LE: Receptors linked to inhibition of adenyl-cyclase: additional signaling mechanisms. FASEB J 1988;2:2686-2695.
12. Watanabe AM: Recent advances in knowledge about beta-adrenergic receptors: application to clinical cardiology. J Am Coll Cardiol 1983;1:82-89.
13. Frishman WH, Charlap S: α-adrenergic blockers. Med Clin North Am 1988;72:427-440.
14. 1-blockade. Am J Hypertens 1989;2:729-735.
15. Doxazosin: long-acting β blocker for hypertension and prostatic hypertrophy. Drug Therapy Perspect 1995;6:5-8.
16. Singleton W, Dix RK, Monsen L, Moisey D, Levenstein M, Bottiglieri DF, Silver L: Efficacy and safety of minipress XL, a new once-a-day formulation of prazosin. Am J Med 1989;87(2A):45S-52S.
17. Van Zwieten PA: Pharmacology profile of urapadil. Am J Cardiol 1989;64:1D-6D.
18. Elliott HL, Meredith PA, Vincent J, Reid JL: Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986;21(Suppl. 1):27S-31S.
19. Reid JL, Meredith PA, Elliot HL: Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J 1983;106:1222-1228.
20. Archibald JL: Recent developments in the pharmacology and pharmacokinetics of indoramin. J Cardiovasc Pharmacol 1986;8(Suppl. 2):S16-S19.
21. 1-adrenergic antagonist for hypertension. Med Clin North Am 1988;72:441-448.
22. Wilde MI, McTavish D: Tamsulosin: a review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883-898.
23. Schulman CC, Lock TMTW, Buzelin JM, and the European Tamsulosin Study Group: Tamsulosin 0.4 mg once daily: 2 year follow-up efficacy and safety in 516 symptomatic benign prostatic obstruction patients (abstract). J Urol 1997;157(Suppl. 4):137.
24. Buzelin JM, Fonteyne E, Kontturi M, Witjes WPJ, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597-605.
25. Katz AM, Hager WD, Messineo FC, Pappano AJ: Cellular actions and pharmacology of the calcium channel blocking drugs. Am J Med 1984;77(2B):2-10.
26. Ribner HS, Bresnahan D, Hsieh AM: Acute hemodynamic responses to vasodilation therapy in congestive heart failure. Prog Cardiovasc Dis 1982;25:1-42.
27. Grimm RH, Flack JM, Schoenberger JA, Gonzalez NM, Liebson PR: a blockade and thiazide treatment of hypertension: a double-blind randomized trial comparing doxazosin and hydrochlorothiazide. Am J Hypertens 1996;9:445-454.
28. Gomi T, Ikeda T, Ikegami F: Beneficial effect of α-blocker on hemorheology in patients with essential hypertension. Am J Hypertens 1997;10:886-892.
29. Raij L, Hayakawa H, Coffee K, Guerra J: Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. Am J Hypertens 1997;10:1257-1262.
30. 1-adrenergic receptor antagonism. J Cardiovasc Pharmacol 1998;31(6):833-839.
31. Neaton JD, Grimm RH, Prineas RI, Stamler J, Gradnits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, for the Treatment of Mild Hypertension Study Research Group: Treatment of mild hypertension study: final results. JAMA 1993;270(6):713-724.
32. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM for the ALLHAT Research Group: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.
33. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG for the Dept of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men: a comparison of six antihypertensives with placebo. N Engl J Med 1993;328:914-921.
34. Johnson BF, Danylchuk MA: The relevance of plasma lipid changes with cardiovascular drug therapy. Med Clin North Am 1989;73:449-473.
35. Levy D, Walmsley P, Levenstein M for the Hypertension and Lipid Trial Study Group: Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996;131:966-973.
36. Andersson P-E, Lithell H: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996;9:323-333.
37. Hachamovitch R, Strom JA, Sonnenblick EH, Frishman WH: Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy. Curr Probl Cardiol 1988;13:371-421.
38. Schobel HP, Langenfeld M, Gatzka C, Schmieder RE: Treatment and post-treatment effects of a versus βreceptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 1996;132:1004-1009.
39. Veelken R, Schmieder RE: Overview of alpha-1 adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens 1996;9:139S-149S.
40. Shigetomi S: Alpha-adrenoceptor antagonist (blocker). Nippon Rinsho 1997;55:2055-2060.
41. Maheux P, Facchini F, Jeppesen J, Greenfield MS, Clinkingbeard C, Chen YD, Reaven GM: Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension: comparison between non-diabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens 1994;7:416-424.
42. Lithell HO: Consideration in the treatment of insulin resistance and related disorders with a new sympatholytic agent. J Hypertens 1997;15(1):S39-S42.
43. Lepor H: Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clinics N Am 1990;17(3):651-659.
44. Gould L, Reddy CVR: Phentolamine. Am Heart J 1976;92:397-402.
45. Majid PA, Sharma B, Taylor SH: Phentolamine for vasodilator treatment of severe heart failure. Lancet 1971;2:719-724.
46. Packer M: Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol 1983;2:841-852.
47. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-Heft). N Engl J Med 1986;314:1547-1552.
48. Kukin ML, Kalman J, Mannino M, Freudenberger R, Buchholz C, Ocampo O: Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 1996;77:486-491.
49. Scholz H: Inotropic drugs and their mechanisms of action. J Am Coll Cardiol 1984;4:389-397.
50. Orlick AE, Ricchi DR, Alderman EL, Stinson EB, Harrison DC: Effects of alpha adrenergic blockade upon coronary hemodynamics. J Clin Invest 1978;62:459-467.
51. Winniford MD, Flipchuk N, Hillis DL: Alpha-adrenergic blockade for variant angina: a long-term double-blind randomized trial. Circulation 1983;67:1185-1188.
52. Gregorini L, Marco J, Palombo C, Kozakova M, Battista Anguissola G, Cassagneau B, Bernies M, Distante A, Marco I, Fajadet J, Zanchetti A: Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. J Am Coll Cardiol 1998;31:992-1101.
53. Corr PB, Shayman JA, Kramer JB, Kipnis KJ: Increased α-adrenergic receptors in ischemic cat myocardium: a potential mediator of electrophysiological derangements. J Clin Invest 1981;67:1232-1236.
54. Manger WM, Gifford RW: Pheochromocytoma. New York: Springer-Verlag, 1977.
55. Honston MC, Thompson WL, Robertson D: Shock: diagnosis and management. Arch Intern Med 1984;144:1433-1439.
56. Fein SA, Frishman WH: The pathophysiology and management of pulmonary hypertension. Cardiol Clin 1987;5:563-576.
57. Cohen ML, Kronzon I: Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension. Ann Intern Med 1981;95:591-593.
58. Henderson WR, Shelhamer JH, Reingold DB, Smith LJ, Evans R III, Kaliner M: Alpha-adrenergic hyper-responsiveness in asthma: analysis of vascular and pupillary responses. N Engl J Med 1979;300:642-647.
59. 1-adrenoceptor antagonist, partially inhibits exercise-induced asthma. J Allergy Clin Immunol 1981;68:411-415.
60. Paterna S, Pinto A, Arrostuto A, Cannavo MG, DiPasquale P, Cottone C, Licata G: Raynaud's phenomenon: effects of terazosin. Minerva Cardioangiol 1997;45:215-221.
61. Karlen RG, Maisel RH: Terazosin blockade of nicotine-induced skin flap necrosis in rat. Arch Otolarynol Head Neck Surg 1997;123:837-840.
62. Hedlund H, Andersson KE, Ek A: Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983;130:275-278.
63. Lepor H: Tamsulosin, long-term, open-label extension study to evaluate therapeutic response and safety (abstract). J Urol 1997;157(Suppl. 4):331.
64. Ramsay JW, Scott GI, Whitfield HN: A double-blind controlled trial of a new α blocking drug in the treatment of bladder outflow obstruction. Br J Urol 1985;57:657-659.
65. Buzelin JM, Delauche-Cavallier MC, Roth S, Geffriand-Ricouard C, Santoni JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997;79:898-906.
66. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia: ALGEBI study group. Eur Urol 1997;31:190-198.
67. Heimbach D, Muller SC: Treatment of benign prostatic hyperplasia with alpha-1-adrenoreceptor antagonists. Urologe 1997;36:18-34.
68. Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K: Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. J Clin Pharm 1998;38:1072-76.
69. van Zwieten PA: α-adrenoceptor blocking agents in the treatment of hypertension. In, Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis and Management. Vol. 2. New York: Raven, 1995;2917-2935.
70. van Zwieten PA: α-adrenergic blocking drugs. In, Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL (eds.): Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994;113-124.
71. Marshall HJ, Beevers DG: α-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility. Br J Clin Pharmacol 1996;42:507-509.
72. Pickering TG, Levenstein M, Walmsley P for the Hypertension and Lipid Trial Study Group: Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure: results of the HALT study. Am J Hypertens 1994;7:844-847.